Pembrolizumab Injection [Keytruda]
Phase 2UNKNOWN 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Gestational Trophoblastic Neoplasia
Conditions
Gestational Trophoblastic Neoplasia
Trial Timeline
Jun 1, 2020 → May 1, 2023
NCT ID
NCT04303884About Pembrolizumab Injection [Keytruda]
Pembrolizumab Injection [Keytruda] is a phase 2 stage product being developed by Merck for Gestational Trophoblastic Neoplasia. The current trial status is unknown. This product is registered under clinical trial identifier NCT04303884. Target conditions include Gestational Trophoblastic Neoplasia.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06180733 | Phase 2 | Recruiting |
| NCT04931979 | Phase 2 | Recruiting |
| NCT04303884 | Phase 2 | UNKNOWN |
Competing Products
18 competing products in Gestational Trophoblastic Neoplasia
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| somatropin | Eli Lilly | Phase 3 | 77 |
| Insulin LISPRO + Insulin, Long-Acting and Insulin | Eli Lilly | Approved | 85 |
| Camrelizumab plus apatinib CohortA + Camrelizumab plus apatinib Cohort B | Jiangsu Hengrui Medicine | Phase 2 | 52 |
| recombinant somatropin | Merck | Pre-clinical | 23 |
| Recombinant human growth hormone (r-hGH) | Merck | Phase 3 | 77 |
| Avelumab Injection + Methotrexate 1 GM Injection | Merck | Phase 1/2 | 41 |
| Saizen® + Saizen® | Merck | Phase 3 | 77 |
| Metformin + placebo | Novo Nordisk | Approved | 84 |
| Metformin XR plus placebo + Metformin XR plus liraglutide | Novo Nordisk | Phase 3 | 76 |
| Somapacitan + Norditropin® | Novo Nordisk | Phase 2 | 51 |
| Liraglutide + Placebo | Novo Nordisk | Approved | 84 |
| Genotropin (PN-180,307) Somatropin + Control-no treatment | Pfizer | Phase 3 | 76 |
| growth hormone | Pfizer | Pre-clinical | 22 |
| Somatropin | Pfizer | Pre-clinical | 22 |
| Somatropin | Pfizer | Pre-clinical | 22 |
| Genotropin (somatropin) | Pfizer | Approved | 84 |
| Omnitrope | Sandoz Group | Approved | 82 |
| Inhaled Technosphere Insulin | MannKind Corp | Phase 2/3 | 60 |